SCHEMBL17329255

SCHEMBL17329255

O=C(Nc1ccc(S(=O)(=O)NC2CCOC2=O)cc1)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.52
▸ MMP9 P14780 3/20 0.51
▸ MEN1 O00255 6/20 0.51
▸ KMT2A Q03164 6/20 0.51
▸ MAPT P10636 3/20 0.50
▸ MMP2 P08253 2/20 0.50
▸ GAA P10253 1/20 0.49
▸ POLB P06746 3/20 0.48
▸ MITF O75030 2/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ CA9 Q16790 2/20 0.47
▸ CA12 O43570 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17329250 1.00 ATM (0.52) ATMMMP9MEN1KMT2AMAPT
SCHEMBL17329258 0.86 MEN1 (0.56) MEN1KMT2APOLBMITFNPC1
SCHEMBL17329231 0.86 MEN1 (0.52) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL17329223 0.86 MEN1 (0.47) MEN1KMT2AMAPTMMP2POLB
SCHEMBL17329201 0.86 MEN1 (0.56) MMP9MEN1KMT2AMAPTGAA
SCHEMBL17329230 0.86 MEN1 (0.52) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL17329224 0.86 MEN1 (0.47) MEN1KMT2AMAPTMMP2POLB
SCHEMBL17329259 0.86 MEN1 (0.56) MEN1KMT2APOLBMITFNPC1
SCHEMBL17329200 0.86 MEN1 (0.56) MMP9MEN1KMT2AMAPTGAA
SCHEMBL17329184 0.86 PRMT1 (0.52) MMP9MEN1KMT2AMMP2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630939-B2 Derivative of homoserine lactone, and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 — — US disclosed
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-12-24 — — US disclosed
EP-2955174-A1 DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2015-12-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof LSS, HES1, SOS1 ATM 2041/4885MMP9 3203/4885MEN1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback